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This issue includes information from the innovative research
ongoing in breast cancer to increase our eﬃcacy and thera-
peutic choices to adequately treat breast cancers with breast
conservation. First a couple of articles address the biologic
issues that form the basis of current therapies and how these
may be improved with new biologic understandings. We are
beginningtorecognizethatthebreastisnotonepairedorgan
but two collections of intertwined ductal lobular trees. Most
if not all breast cancers only involve a single ductal tree at
the time of clinical detection. All the other ductal trees are
at risk and may have both synchronous and metachronous
lesions that can progress or regress based on biologic and
environmental pressures. As we understand breast cancer
biology better we may have opportunities to detect cancers
earlier, prevent cancers, and optimize conservation with
more accurate and precise treatment.
Oncoplastic surgery has given the prospect of breast
conservation with reasonable cosmetic outcomes to more
and more patients. It now becomes more important through
biology and imaging that we accurately predict the extent of
disease and treat with a single surgical intervention. Articles
in this issue highlight these issues, challenges, and potential
successful resolutions. It would seem now that 50–80% or
more of stage 0–2 breast cancers could be treated equally as
well through modern conservation techniques.
One of the requirements for most patients now for breast
conservation is radiation therapy. This has been historically
very costly in both equipment and time commitment. New
technologies and approaches are leading to much shorter
treatment times and treatment volumes than the classic
whole breast treated 5days/week for 6–8 weeks. To make
breast conservation more accessible in the less aﬄuent parts
of the world, we need short treatment times with min-
imal equipment and infrastructure investments. Several au-
thors have presented data in this issue on evolving tech-
nologies including accelerated partial breast irradiation and
targeted intraoperative radiotherapy. A single fraction of
radiotherapy given during surgery directly to the tumor bed
(intraoperative radiotherapy) avoids many of the prior prob-
lems. The rationale and level 1 evidence for the safety and
eﬃcacyoftheseapproachesarereviewedandsuggestthatour
ability to bring robust eﬀective breast conservation irradia-
tion to the entire world is soon going to be within our grasp.
The next two decades will see an explosion of breast can-
cer cases worldwide. Breast cancer becomes more common
as countries gain in GDP (Gross Domestic Product). Rates
for breast cancer in many parts of the world will reach that
of Western Europe and North America. With this impeding
public health problem, we need better screening, precise and
costeﬀectivetreatment,andsurvivorshipnotunencumbered
by complications and toxicities of our therapies. This issue
brings data and ideas that oﬀer a glimmer that breast
conservation can become the most common treatment
worldwide-not just in the aﬄuent West.
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